TABLE 3

Current clinical trials targeting the AR-signaling pathway in prostate cancer

AgentClinicaltrials.gov
Identifier
PhaseMechanism of ActionObjectivesRef
HydroxyflutamideNCT02341404IIAntiandrogenCharacterize and quantify the histopathological changes in the surgical specimens(Gupta et al., 2017)
EnzalutamideNCT01927627IIAntiandrogenEvaluating the clinical activity and safety of Enza in men with high-risk PC(Ornstein et al., 2016)
Apalutamide (ARN-509)NCT02770391IIAntiandrogenDetermine if neo-adjuvant leuprolide and ARN-509 have different effects on DHT levels in benign prostate tissue. Evaluate the differential effect of neoadjuvant leuprolide and ARN-509 on other androgens(Al-Salama, 2018; Smith et al., 2016)
BicalutamideNCT00846976IIIAntiandrogenCheck the health of patients receiving a 200 mg daily dose of CASODEX.(Laufer et al., 1999; Osguthorpe and Hagler, 2011)
FlutamideNCT00006214IIAntiandrogenDetermine the ability of flutamide to reduce the incidence of PC in patients with high-grade prostatic intraepithelial neoplasia(Eisenberger et al., 1998)
DarolutamideNCT04157088IIIAntiandrogenCompare the effects of the drug darolutamide and drug Enza on physical function, including balance and daily activity, in patients with castration-resistant PC(Fizazi et al., 2019)
GaleteroneNCT01709734IIAntiandrogenTwo-part trial to evaluate the safety and efficacy of galeterone in CRPC patients(Bastos and Antonarakis, 2016)
NilutamideNCT00918385IIAntiandrogenDetermine the clinical impact of using a patient-specific genomic expression signature of AR activity to determine therapy for patients with CRPC.(Dole and Holdsworth, 1997)